Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
NCT06465238Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tizetatug rezetecan, ruzaltatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tizetatug rezetecanruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06465238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465238.